Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study

被引：0

作者：

Sborov, Douglas ^{[1
]}

Baljevic, Muhamed ^{[2
]}

Reeves, Brandi ^{[3
]}

Laubach, Jacob ^{[4
]}

Efebera, Yvonne ^{[5
]}

Rodriguez, Cesar ^{[6
]}

Costa, Luciano ^{[7
]}

Chari, Ajai ^{[8
]}

Silbermann, Rebecca ^{[9
]}

Holstein, Sarah ^{[1
]}

Anderson, Larry D., Jr. ^{[10
]}

Kaufman, Jonathan ^{[11
]}

Shah, Nina ^{[12
]}

Pei, Huiling ^{[13
]}

Patel, Sharmila ^{[14
]}

Cortoos, Annelore ^{[14
]}

Bartlett, Blake ^{[15
]}

Vermeulen, Jessica ^{[16
]}

Lin, Thomas ^{[14
]}

Voorhees, Peter ^{[17
]}

Richardson, Paul G. ^{[4
]}

机构：

[1] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ Nebraska Med Ctr, Div Oncol & Hematol, Dept Internal Med, Omaha, NE USA

[3] Univ N Carolina, Chapel Hill, NC 27515 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] OhioHealth, Columbus, OH USA

[6] Mt Sinai Tisch Canc Inst, New York, NY USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[9] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[10] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Sci Affairs LLC, Horsham, PA USA

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Leiden, Netherlands

[17] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-180

引用

页码：S135 / S136

页数：2

共 50 条

[1] Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Sborov, Douglas W.
Baljevic, Muhamed
Reeves, Brandi
Laubach, Jacob
Efebera, Yvonne A.
Rodriguez, Cesar
Costa, Luciano J.
Chari, Ajai
Silbermann, Rebecca
Holstein, Sarah A.
Anderson, Larry D., Jr.
Kaufman, Jonathan L.
Shah, Nina
Pei, Huiling
Patel, Sharmila
Cortoos, Annelore
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Voorhees, Peter M.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 355 - 365
[2] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
Nooka, Ajay
Kaufman, Jonathan
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah
Anderson, Larry
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas
Usmani, Saad
Richardson, Paul
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
[3] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Shune, Leyla
Badros, Ashraf
Chari, Ajai
Richardson, Paul G.
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Hoehn, Daniela
Lin, Thomas S.
Voorhees, Peter M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
[4] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2020, 136
[5] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138
[6] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Anderson, Larry D., Jr.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Voorhees, Peter M.
Richardson, Paul G.
BLOOD, 2021, 138
[7] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
Voorhees, Peter M.
Rodriguez, Cesar
Reeves, Brandi
Nathwani, Nitya
Costa, Luciano J.
Lutska, Yana
Bobba, Padma
Hoehn, Daniela
Pei, Huiling
Ukropec, Jon
Qi, Ming
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136
[8] An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne A.
Reeves, Brandi
Wildes, Tanya M.
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf Z.
Shune, Leyla O.
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 10154 - 10156
[9] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134
[10] Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
Rodriguez, Cesar
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Chari, Ajai
Silbermann, Rebecca Wang
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Jakubowiak, Andrzej J.
Orlowski, Robert Z.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →